Clinical trials: CYP19
Genitourinary Syndrome of Menopause
Use of Fractional CO2 Laser Versus Erbium:YAG Laser for the Treatment of GSM in Patients Using Aromatase Inhibitors
To study the efficacy and safety of intravaginal CO2 laser versus intravaginal Er:YAG laser and sham application in alleviating genitourinary symptoms in patients receiving an aromatase inhibitor as adjuvant treatment of breast…
- Trial name
- LASI (NCT05713435)
- Testing
- intravaginal laser
- Where
- Belgium
- Volunteers
- 162 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
RATIONALE: Zoledronic acid may prevent bone loss and help prevent or lessen musculoskeletal symptoms in women receiving hormone therapy for breast cancer.
- Conditions
- Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer
- Trial name
- NCT01194440
- Testing
- letrozole, zoledronic acid
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, Joint Pain
Trial of Blue Citrus Compared to Placebo in Patients Receiving Aromatase Inhibitor Therapy for Estrogen Receptor Positive Post-Menopausal Breast Cancer
This purpose of this study is to determine if the herbal compound, Blue Citrus, decreases joint and bone pain associated with Aromotase Inhibitor therapy (AIT).
- Trial name
- NCT00702858
- Testing
- Blue Citrus
- Volunteers
- 30 people
- Sponsor
- Legacy Health System
ER+ Breast Cancer
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
The addition of entinostat to an AI will result in a maximal abrogation of estrogen receptor-α mediated activity and inhibit mechanisms of resistance to the aromatase inhibitor.
- Trial name
- NCT00828854
- Testing
- Entinostat, Aromatase Inhibitor (AI) Therapy
- Where
- 6 sites in Ireland, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Syndax Pharmaceuticals
Breast Cancer, Arthralgia
Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer
Early stage hormone receptor positive breast cancer is typically treated with adjuvant endocrine therapy in order to decrease risk of breast cancer recurrence and to improve overall survival from the disease.
- Conditions
- Breast Cancer, Arthralgia, Obesity
- Trial name
- LOGRIBMET (NCT01896050)
- Testing
- anastrozole, letrozole, exemestane, Tamoxifen
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- University of Michigan Rogel Cancer Center
Breast Cancer Female
Impact of Pilates Method on Myofascial Stiffness, Cardiorespiratory Fitness and Quality of Life in Breast Cancer Women
The effectiveness of breast cancer treatment is quite well documented. Still, side effects can underpin other treatment-induced diseases such as osteopenia, diabetes, and especially cardiovascular dysfunction.
- Trial name
- NCT06419023
- Testing
- supervised physical activity intervention using the Pilates Method (exercises on the mat)
- Where
- Poland
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Poznan University of Physical Education
Breast Cancer
Yoga for Aromatase Inhibitor-associated Joint Pain
The purpose of this study is to determine whether it might be practical and useful to investigate the effectiveness of yoga classes in relieving joint pain associated with the use of a class of medications known as aromatase…
- Trial name
- NCT01951976
- Testing
- Questionnaires, Yoga Classes
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pregnancy, Unexplained Infertility
Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation
The objective of this application is to identify a pharmacologic agent which helps couples in whom the female partner ovulates regularly successfully obtain their goal of delivering a healthy child, whose use will result in low…
- Trial name
- AMIGOS (NCT01044862)
- Testing
- Letrozole (aromatase inhibitor), Clomiphene Citrate, Follicle Stimulating Hormone (gonadotropin)
- Where
- 14 sites in United States
- Volunteers
- 900 people
- Sponsor
- Yale University
Breast Cancer
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
The purpose of this study is to evaluate oral doses of BMS-754807 in combination with letrozole or BMS-754807 alone are safe and efficacious in locally advanced or metastatic hormone receptor positive breast cancer subjects who…
- Trial name
- NCT01225172
- Testing
- BMS-754807, letrozole
- Where
- 21 sites in United States
- Volunteers
- 77 people
- Sponsor
- Bristol-Myers Squibb
Infertility Due to Azoospermia, Infertility, Male
A Novel Aromatase Inhibitor, Leflutrozole, for Treatment of Non-Obstructive Azoospermia
This clinical interventional study aims to assess whether treatment with with leflutrozole can improve sperm production in infertile men with non-obstructive azoospermia selected by serum anti-mullerian hormone (AMH) or Inhibin B…
- Trial name
- NOVA-NOA (NCT07571928)
- Testing
- Leflutrozole, Dose 2
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Martin Blomberg Jensen
Breast Neoplasm Female, Arthralgia
Trial of Oral Hyaluronic Acid for the Prevention of Aromatase Inhibitor-Associated Arthralgias
This is a single center, double-blinded, placebo-controlled, randomized Phase II trial to determine whether oral hyaluronic acid will prevent aromatase inhibitor (AI)-associated arthralgias.
- Trial name
- NCT03384095
- Testing
- Hyaluronic Acid (HA)
- Where
- 4 sites in United States
- Sponsor
- Erin Newton
Breast Cancer
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
More than three quarter of patients with breast cancer are treated by hormone pills called tamoxifen and aromatase inhibitors (AIs). AIs are drugs that stop female hormone production.
- Trial name
- NCT02095184
- Testing
- Anastrozole, Letrozole
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Maryland, Baltimore
Breast Cancer
Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
Hormone receptor-positive breast cancer accounts for about 70% of all breast cancers. Extended endocrine therapy with aromatase inhibitor is the current main treatment for hormone receptor-positive breast cancer.
- Trial name
- NCT04476485
- Testing
- endocrine therapy
- Where
- 12 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Shengjing Hospital
Neoplasms
Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer
A randomised double blind placebo controlled phase II study of fulvestrant with or without the addition of vandetanib as treatment for patients with metastatic breast cancer resistant to aromatase inhibitor therapy.
- Trial name
- FURVA (NCT02530411)
- Testing
- Fulvestrant, Vandetanib
- Where
- 5 sites in United Kingdom
- Volunteers
- 160 people
- Sponsor
- Velindre NHS Trust
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
This study evaluates changes in skin quality and self-esteem among breast cancer patients who are initiating aromatase inhibitor therapy.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT06401889
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mayo Clinic
Breast Cancer
Musculoskeletal Pain in Postmenopausal, Early Breast Cancer Patients Receiving Aromatase Inhibitor Therapy - A Pilot Study
In 2005, the EBCIG demonstrated the efficacy of tamoxifen in improving overall survival in hormone receptor positive breast cancers.
- Trial name
- AIMS (NCT00653718)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Breast Cancer
Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics
The proposed study plans to examine the effect of flaxseed consumption, a phytoestrogen rich food, compared to aromatase inhibitors as a complementary approach to treating estrogen receptor positive breast cancer, as well as the…
- Trial name
- FABrC (NCT00612560)
- Testing
- Anastrozole, flaxseed
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer
Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors
To see the impact of obesity on the efficacy of adjuvant endocrine therapy with aromatase inhibitors in postmenopausal patients with early breast cancer in terms of: i) Locoregional recurrence ii) Distant metastases iii)…
- Trial name
- NCT01758146
- Testing
- Tamoxifen, Letrozole
- Where
- India
- Volunteers
- 412 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Breast Cancer
Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using anastrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- HORGEN (NCT00871858)
- Testing
- anastrozole, fulvestrant
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Institut Bergonié
Carcinoma Breast Stage IV
Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer
Steroid Aromatase Inhibitors and Non-Steroid Aromatase Inhibitors in Late Stage Breast Cancer is the recommended scheme in National Comprehensive Cancer Network (NCCN) guideline.
- Trial name
- NCT02161315
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital